CyTOF XT PRO System Launches with Innovations for Clinical Trial Research

While the majority of conventional and spectral flow cytometry systems are limited by the number of features that can be analyzed at once, CyTOF platforms offer the widest coverage available to detect more markers at the same time – providing a highly accurate view of biological heterogeneity. Because of this, CyTOF systems have facilitated advancements in cancer immunotherapies, drug target development and broader immunology applications.

The latest CyTOF XT PRO system takes mass cytometry to a new level. Launched on March 24, CyTOF XT PRO is designed to support researchers in clinical trial settings. This fifth generation CyTOF system offers:

• The widest immune coverage, simultaneously analyzing more than 50 markers for more precision in trial design
• Improved throughput, up to four times faster than previous CyTOF systems
• Consistency across a variety of sample collection methods used in clinical settings, reliably returning better than 9.2% CV across workflows and enabling studies to better leverage large cohorts, longitudinal sampling and multi-site collections with accuracy
• Integrated 21 CFR Part 11 compliance-enabled software that meets relevant requirements for clinical research
• Advanced barcoding capabilities of more than 100 samples in a single tube, minimizing technical variability and reducing workflow burdens for clinical trials
• An option for current CyTOF XT users to upgrade their systems to harness the new features of the CyTOF XT PRO platform

What makes CyTOF XT PRO systems different?

CyTOF technology is already a powerful tool for studying how cells function, how diseases develop, and how new treatments can be made safer and more effective. The CyTOF XT PRO system further empowers researchers to analyze immune responses at a scale not possible with other methods, facilitating large immunophenotyping clinical trial initiatives, while meeting regulatory needs for GLP labs.

• CyTOF systems see more details at once: Fluorescence-based flow cytometry methods face significant limitations in the number of features that can be analyzed at once. The CyTOF XT PRO system offers the widest coverage of different cell types detected simultaneously, allowing researchers to cast a bigger net in assessing patient response to clinical trial therapies, catching insights that other platforms miss.
• More reliable and reproducible results: When running clinical trials, researchers need to make sure they get the same results every time. CyTOF technology has exceptionally high reproducibility, as metal-tagged reagents are stable during sample storage, freezing, preservation and shipping. This makes the data more consistent and easier to compare, even if the study is conducted across different locations.
• More samples in less time: The CyTOF XT PRO system can process many samples at once, leveraging barcoding for sample multiplexing. In clinical trials, where hundreds or thousands of samples might need to be tested, less manual work means fewer mistakes and faster results.
• Less interference and more accuracy: Other methods, like flow cytometry, use fluorescent dyes that can overlap and confuse signals. CyTOF systems avoid this problem by using metal tags, so there’s less interference and more precise measurements.
• Walk-away acquisition: The CyTOF XT PRO system offers researchers the ability to load samples and walk away using a chilled sample carousel that holds 13 tubes, plus unique signal optimization providing uninterrupted 23-hour acquisition.

Read more about CyTOF technology

Because CyTOF technology allows scientists to study individual cells in detail, it has become a critical driver for many types of research. CyTOF technology has been featured in over 3,000 peer-reviewed publications and utilized in more than 300 clinical trials.

Learn more about CyTOF XT PRO